Radiation Therapy for Ovarian Cancer: When Is It Used and How Effective Is It?

Ovarian cancer is a severe disease that presents challenges due to late diagnoses and high rates of recurrence. The standard treatments are surgery and platinum-based chemotherapy. In the past, radiation therapy (RT) was commonly used, but its usage decreased over time because of its toxicity and limited benefits for survival. However, new advancements in RT techniques are changing how it is used, especially for recurrent cases or for relieving symptoms. This blog looks at when radiation therapy is used in ovarian cancer and examines its effectiveness, patient benefits, and evolving uses.

Before suggesting RT, doctors assess:

Tumor type and sensitivity to radiation
Recurrence location and size
Previous treatments and overall toxicity
The patient's health and needs for preserving fertility

The Historical Role of Radiation in Ovarian Cancer

Before the era of chemotherapy, whole abdominal irradiation (WAI) was used after surgery to remove microscopic disease from the abdomen and pelvis. It may follow chemotherapy or surgery to help reduce the symptoms of advanced cancer, or it can be used alone as a palliative treatment. While early studies suggested some benefits in controlling early-stage disease locally, severe side effects - such as damage to the bowel, bladder, and bone marrow - led to a decline in its use. RT was replaced by more effective chemotherapy regimens, especially platinum-based treatments that target the cancer throughout the body.

During each radiation therapy session, you will lie on a treatment table under a large machine that delivers radiation to the affected areas. You will not feel anything during the treatment, which lasts only a few minutes. You may spend a total of 10 to 20 minutes in the room for each appointment. The number of radiation therapy sessions you receive will depend on several factors, including the type and size of the cancer and its location. You may require a few treatments, or you may need daily treatments for several weeks.

Current Indications for Radiation Therapy

Salvage or palliative RT: RT is now primarily used to manage symptoms or treat localised recurrences that canâ€™t be addressed by surgery or further chemotherapy.
Oligo-recurrent disease: Modern methods like involved-field RT or stereotactic body RT (SBRT) provide targeted treatment to limited metastatic areas, achieving impressive local control rates of 89â€“100%.
Select histologies: Some ovarian tumor types - like sex-cord stromal tumors or clear cell carcinomas - are more sensitive to radiation and may, in rare instances, be candidates for consolidation RT in early-stage cases.

Why was radiation therapy largely discontinued?

The side effects of WAI, especially to the gastrointestinal and blood-forming tissues, made it hard to tolerate and caused long-term issues. Chemotherapy proved to be more effective in treating both small metastatic and obvious disease in the abdomen and pelvis. With about 70% of patients experiencing local recurrence after initial treatment, RT was often postponed to prevent additional toxicity.

Advances in Radiotherapy Techniques

Intensity-Modulated Radiation Therapy (IMRT) and Volumetric Modulated Arc Therapy (VMAT) offer WAI using lower doses, resulting in fewer side effects compared to older methods.
Stereotactic Body RT (SBRT) is now a precise approach to delivering high doses of radiation over a few sessions (like 30 Gy in 3 - 5 fractions) to isolated metastases, achieving local control rates of up to 96% at 6 months.
Intraoperative radiation therapy (IORT) delivers a radiation boost directly to the tumor during surgery, reducing exposure to surrounding tissues.

New methods, such as proton therapy and dose painting techniques, including AI-based motion tracking, help improve the targeting of the tumour while protecting healthy organs.

Radiation therapy compared to other therapies.

Feature	Radiation Therapy (e.g., SBRT / IMRT)	Systemic Therapy (Chemotherapy/Immunotherapy)
Local Control	High in targeted lesions	Lower control in isolated pelvic nodal disease
Toxicity	Low with modern techniques	High (e.g., nausea, marrow suppression)
Treatment-Free Interval	Extended after RT in a salvage setting	Continuous exposure, treatment fatigue
Systemic Disease Role	Limited. Radiation doesnâ€™t treat widespread disease	Effective for microsatellite and distant disease control

When Is Radiation Used Today?

Recurrent or progressive disease: RT is considered when the disease comes back in specific areas, such as para-aortic nodes or pelvic sites, especially after several rounds of chemotherapy.

Palliative treatment: RT can relieve symptoms such as pain, bleeding, or pressure from masses in advanced cases, providing control when systemic therapy is insufficient.
Consolidation in select early-stage cases: Rare cases - like high-grade Stage I or II tumors with little remaining disease - might benefit from controlled pelvic RT.
Histology-specific indications: Ovarian clear cell carcinoma and stromal subtypes might respond better to RT when recurrence is localised.

Effectiveness and Outcomes

Salvage SBRT: Phase II trials show up to 96% local control, a median overall survival of around 20 months, and few severe side effects (grade â‰¥3).
IMRT-WAI: Phase I/II studies indicate that over 70% of patients tolerated WAI well, with an acceptable impact on their quality of life, suggesting it is suitable in consolidation situations.

When used for localised recurrences, RT provides longer breaks from chemotherapy and delays progression, improving patient quality of life.

Side Effects and Toxicities

Pelvic radiation can lead to side effects like diarrhoea, urinary problems, vaginal narrowing, lumbosacral plexopathy, and, in a few patients, osteonecrosis.
Radiation to the ovaries or uterus can cause ovarian failure or early menopause, which is significant for younger patients.

Modern techniques, such as SBRT, IMRT, and proton therapy, help minimise exposure to healthy tissue and reduce long-term effects.

Who Might Benefit Most?

Patients with solitary or few metastatic recurrences, especially small lesions in the pelvic area or lymph nodes, may achieve lasting local control with SBRT.

Specifically, these are early-stage patients without significant residual disease and with favourable tumour types.
Those needing relief from local symptoms or bleeding in hard-to-treat cases.
RT remains underused but is a promising option within a team-based treatment approach.

Conclusion

Improving AI-guided motion tracking, adaptive radiotherapy, and carbon-ion treatments may further enhance precision and outcomes. Combining RT with immunotherapy or medications that increase radiation sensitivity might boost tumor destruction and extend remission. Clinical trials are necessary to define and broaden RT's uses in epithelial ovarian cancer, particularly for salvage and consolidation situations.

Radiation therapy is no longer the first choice for managing ovarian cancer. However, it has found a renewed role in modern oncology as a focused and effective option for salvage, consolidation, and palliation. With new techniques like SBRT, IMRT, and proton therapy, RT offers high local control rates and manageable side effects for carefully chosen patients. As research progresses and technology improves, RT may regain a more significant position in the comprehensive care of ovarian cancer, especially for recurrences and limited metastatic disease.